Entos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy
EDMONTON, Alberta & SAN DIEGO — Entos Pharmaceuticals Inc (Entos), a clinical-stage company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV delivery platform is proud to announce a collaboration with the L-CMD Research Foundation, a nonprofit that urgently translates scientific research into treatments for LMNA-related congenital muscular dystrophy (L-CMD). At least 200 children […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.